Payment overview · 2025
General Payments
$1,209.69
64 reported records · 20 companies
Healthcare provider profile · identity verified
Daniel Riegel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HOWARD BEACH, NY · NPI 1265792527
Verified facts
What the public records show
CMS Open Payments records show Daniel Riegel, M.D. received $1,209.69 in general payments during 2025 across 64 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 17.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Edarbi, Eliquis, Jardiance, Mounjaro, Verquvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Farxiga by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Edarbi by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 417 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nexlizet by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $211.12 | 17.4% | 20 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $137.72 | 11.4% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $113.99 | 9.4% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $103.81 | 8.6% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $76.14 | 6.3% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $73.81 | 6.1% | 3 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $66.15 | 5.5% | 4 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $60.09 | 5.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $56.61 | 4.7% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $44.36 | 3.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.97 | 3.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.50 | 2.7% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $31.90 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.50 | 2.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.05 | 2.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.75 | 2.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.40 | 1.9% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $20.86 | 1.7% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.37 | 1.6% | 1 | 2025 |
| VivaQuant Inc, dba Rhythm Express | Unresolved — no canonical attribution shown | $17.59 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,209.69 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $137.72 | 5 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $113.99 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $103.81 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $94.50 | 9 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $83.93 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $76.14 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $73.81 | 3 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $66.15 | 4 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $60.09 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $56.61 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $44.36 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.97 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.97 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $31.90 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.50 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.05 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| RHYTHM EXPRESS Normalized: rhythm express |
Device | VivaQuant Inc, dba Rhythm Express | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EDARBI edarbi |
2025 | Edarbi | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 417 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 39 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 134 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
170 | 55 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | 20 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
417 | 152 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
134 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
67 | 16 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
162 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1054 | 445 |
| Metoprolol Succinate | Metoprolol Succinate | 812 | 312 |
| Amlodipine Besylate | Amlodipine Besylate | 563 | 240 |
| Eliquis | Apixaban | 417 | 152 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 402 | 178 |
| Losartan Potassium | Losartan Potassium | 389 | 163 |
| Furosemide | Furosemide | 361 | 166 |
| Pantoprazole Sodium | Pantoprazole Sodium | 332 | 138 |
| Levothyroxine Sodium | Levothyroxine Sodium | 301 | 113 |
| Clopidogrel | Clopidogrel Bisulfate | 300 | 127 |
| Metoprolol Tartrate | Metoprolol Tartrate | 207 | 92 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 86 |
| Simvastatin | Simvastatin | 180 | 71 |
| Metformin Hcl | Metformin Hcl | 178 | 85 |
| Farxiga | Dapagliflozin Propanediol | 170 | 55 |
| Entresto | Sacubitril/Valsartan | 162 | 44 |
| Alprazolam | Alprazolam | 158 | 51 |
| Ezetimibe | Ezetimibe | 145 | 52 |
| Carvedilol | Carvedilol | 140 | 63 |
| Mounjaro | Tirzepatide | 134 | 24 |
| Omeprazole | Omeprazole | 134 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 57 |
| Repatha Sureclick | Evolocumab | 129 | 39 |
| Xarelto | Rivaroxaban | 124 | 42 |
| Lisinopril | Lisinopril | 119 | 55 |
| Ozempic | Semaglutide | 117 | 39 |
| Nifedipine Er | Nifedipine | 105 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 40 |
| Atenolol | Atenolol | 98 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 97 | 44 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 96 | 49 |
| Gabapentin | Gabapentin | 95 | 41 |
| Januvia | Sitagliptin Phosphate | 88 | 30 |
| Spironolactone | Spironolactone | 84 | 41 |
| Methylprednisolone | Methylprednisolone | 77 | 57 |
| Enalapril Maleate | Enalapril Maleate | 69 | 25 |
| Torsemide | Torsemide | 69 | 28 |
| Glimepiride | Glimepiride | 68 | 26 |
| Trulicity | Dulaglutide | 67 | 16 |
| Synthroid | Levothyroxine Sodium | 64 | 24 |
| Allopurinol | Allopurinol | 61 | 26 |
| Finasteride | Finasteride | 61 | 24 |
| Famotidine | Famotidine | 58 | 34 |
| Clonazepam | Clonazepam | 57 | 15 |
| Potassium Chloride | Potassium Chloride | 56 | 31 |
| Prasugrel Hcl | Prasugrel Hcl | 55 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 52 | 19 |
| Sertraline Hcl | Sertraline Hcl | 51 | 19 |
| Tramadol Hcl | Tramadol Hcl | 51 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 28 |
| Labetalol Hcl | Labetalol Hcl | 50 | 16 |
| Montelukast Sodium | Montelukast Sodium | 50 | 23 |
| Cilostazol | Cilostazol | 49 | 22 |
| Azithromycin | Azithromycin | 47 | 41 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 36 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 21 |
| Valsartan | Valsartan | 43 | 14 |
| Amoxicillin | Amoxicillin | 42 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 17 |
| Naproxen | Naproxen | 42 | 14 |
| Ramipril | Ramipril | 42 | 19 |
| Metformin Hcl Er | Metformin Hcl | 40 | 18 |
| Jardiance | Empagliflozin | 39 | 20 |
| Candesartan Cilexetil | Candesartan Cilexetil | 36 | 13 |
| Prednisone | Prednisone | 36 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 16 |
| Meclizine Hcl | Meclizine Hcl | 35 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 30 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Bumetanide | Bumetanide | 33 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | 15 |
| Lorazepam | Lorazepam | 32 | suppressed |
| Praluent Pen | Alirocumab | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 13 |
| Glipizide | Glipizide | 27 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Lovastatin | Lovastatin | 24 | 11 |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 22 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | 16 |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Colchicine | Colchicine | 17 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Wegovy | Semaglutide | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 14 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Edarbi | Azilsartan Medoxomil | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | suppressed |
| Verquvo | Vericiguat | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,209.69 · 64 records | E.R. Squibb & Sons, L.L.C. | AIRSUPRA, AMVUTTRA, Attruby, CAMZYOS, CARDIOMEMS, CREON, Cologuard Collection Kit, ECC Solutions, EDARBI, ELIQUIS, FFRct, JARDIANCE, Kerendia, LEQVIO, LINZESS, MOUNJARO, NEXLETOL, REPATHA, RHYTHM EXPRESS, SAPIEN 3 Ultra RESILIA, UBRELVY, VERQUVO, WATCHMAN FLX, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Edarbi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error